Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL and CINVANTI. Its pipeline product is HTX-011.
| Website: | www.herontx.com |
| Email: | info@herontx.com |
| Main Phone: | +1 858 251-4400 |
| Address: | 4242 Campus Point Court |
| Address 2: | Suite 200 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Barry D. Quart |
| Employees: | 145 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 26.93 | Change $ 0.38 | Change % 1.43 | Tick N/A |
| Bid 25.55 | Bid Size 500.00 | Ask 27.49 | Ask Size 400.00 |
| Open 26.55 | High 27.10 | Low 25.87 | Prev Close 26.55 |
| Last Trade | Volume 617,073 | 52 Wk Hi 42.90 | 52 Wk Low 15.00 |
| Market Cap 2.1 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 78,019,031.00 | EPS (TTM) -2.94 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 5 | 10 |
| Number of Buys | 3 | 6 |
| Number of Sells | 2 | 4 |
| Net Activity | 192308 | 192844 |
| Last 10 Buys | Shares |
|---|---|
| Kevin C. Tang | 1,000 |
| John W. Poyhonen | 1,000 |
| Kevin C. Tang | 1,000 |
| Kevin C. Tang | 1,000 |
| Kevin C. Tang | 1,000 |
| Kevin C. Tang | 1,000 |
| Kevin C. Tang | 1,000 |
| Kevin C. Tang | 1,000 |
| Barry D. Quart | 1,000 |
| Barry D. Quart | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Kimberly J. Manhard | 1,000 |
| Barry D. Quart | 1,000 |
| Barry D. Quart | 1,000 |
| Kimberly J. Manhard | 1,000 |
| Kimberly J. Manhard | 1,000 |
| Robert H. Rosen | 1,000 |
| Robert H. Rosen | 1,000 |
| Robert H. Rosen | 1,000 |
| Robert H. Rosen | 1,000 |
| Robert H. Rosen | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 56 | 56 | 56 | 56 |
| Low Target Price Estimate | 30 | 30 | 30 | 30 |
| Mean Target Price Estimate | 39.91 | 39.91 | 39.91 | 39.91 |
| Standard Deviation | 9.01 | 9.01 | 9.01 | 9.01 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 10-Q | Quarterly report with a continuing view of a company's financial position | 83 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-10 |
| DEFA14A | Additional proxy soliciting materials - definitive | 3 | 2018-04-30 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 56 | 2018-04-30 |
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 56 | 2018-04-19 |
| 8-K | Report of unscheduled material events or corporate changes. | 57 | 2018-04-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-02 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 45 | 2018-03-30 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 44 | 2018-03-28 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-19 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 8 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.09 | 1.09 | 1.09 | 1.11 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
